Pharmafile Logo
Pharmafocus logo
Advanced Search

olysio

Showing 7 posts of 7 posts found.

Janssen sales follow J&J’s downward trend

July 15, 2015
Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio

Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …

News

NICE recommends hep C and bowel treatments

February 26, 2015
Sales and Marketing AbbVie, Humira, J&J, JJ, Janssen, Merck, Remicade, Simponi, olysio

Three drugs to treat chronic bowel condition ulcerative colitis and one for hepatitis C will be funded by the NHS …

News
J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

News
Olysio image

Janssen privy to new pricing scheme and see NICE nod

January 16, 2015
Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir

Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …

News
jj_building_0

New drugs see J&J sales rise

July 17, 2014
Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi

Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …

News
J&J image

J&J profits up amid drug gains

January 23, 2014
Sales and Marketing FDA, J&J, JJ, Remicade, Zytiga, olysio, q4

Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …

News
janssen image

FDA approves Olysio

November 25, 2013
Sales and Marketing FDA, Janseen, Janssen, hep C, hepc, olysio, simeprevir

US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024